I
144.28
-4.43 (-2.98%)
| 前收盘价格 | 148.71 |
| 收盘价格 | 148.87 |
| 成交量 | 150,792 |
| 平均成交量 (3个月) | 236,249 |
| 市值 | 3,646,215,168 |
| 预期市盈率 (P/E Forward) | 19.92 |
| 价格/销量 (P/S) | 1.52 |
| 股市价格/股市净资产 (P/B) | 1.86 |
| 52周波幅 | |
| 利润日期 | 5 May 2025 - 9 May 2025 |
| 营业毛利率 | -4.94% |
| 营业利益率 (TTM) | 7.31% |
| 稀释每股收益 (EPS TTM) | -4.69 |
| 季度收入增长率 (YOY) | 7.10% |
| 总债务/股东权益 (D/E MRQ) | 83.59% |
| 流动比率 (MRQ) | 2.59 |
| 营业现金流 (OCF TTM) | 204.03 M |
| 杠杆自由现金流 (LFCF TTM) | 77.01 M |
| 资产报酬率 (ROA TTM) | 1.42% |
| 股东权益报酬率 (ROE TTM) | -5.76% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Instruments & Supplies (US) | 混合的 | 混合的 |
| Medical Instruments & Supplies (全球的) | 混合的 | 混合的 | |
| 股票 | ICU Medical, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
-2.8
| 分析师共识 | NA |
| 内部交易活动 | -3.0 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -3.5 |
| 平均 | -2.75 |
|
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically. |
|
| 部门 | Healthcare |
| 行业 | Medical Instruments & Supplies |
| 投资方式 | Small Core |
| 内部持股比例 | 7.84% |
| 机构持股比例 | 99.83% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合